Active	Status	Sponsor type	Region	Phase	Filter
8 Active 0 Inactive 8 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes: « April » « 2025 » M T W T F S S 31 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 1 2 3 4   - « April » « 2025 » M T W T F S S 31 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 1 2 3 4   Show only changed items Enrollment:

Advanced Filters

8 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Gammon, John
MUIR-3, NCT06347133: Phase 3 Study of Plozasiran in Adults With Hypertriglyceridemia	Recruiting	3	1328	Europe, Canada, US, RoW	Plozasiran Injection, ARO-APOC3, Placebo	Arrowhead Pharmaceuticals	Hypertriglyceridemia	07/26	10/26
SHASTA-3, NCT06347003: Study of Plozasiran (ARO-APOC3) in Adults With Severe Hypertriglyceridemia	Recruiting	3	405	Europe, Canada, US, RoW	Plozasiran Injection, ARO-APOC3, Placebo	Arrowhead Pharmaceuticals	Severe Hypertriglyceridemia	07/26	10/26
Watwe, Veena
MUIR-3, NCT06347133: Phase 3 Study of Plozasiran in Adults With Hypertriglyceridemia	Recruiting	3	1328	Europe, Canada, US, RoW	Plozasiran Injection, ARO-APOC3, Placebo	Arrowhead Pharmaceuticals	Hypertriglyceridemia	07/26	10/26
SHASTA-3, NCT06347003: Study of Plozasiran (ARO-APOC3) in Adults With Severe Hypertriglyceridemia	Recruiting	3	405	Europe, Canada, US, RoW	Plozasiran Injection, ARO-APOC3, Placebo	Arrowhead Pharmaceuticals	Severe Hypertriglyceridemia	07/26	10/26
LUCIDITY, NCT06747468: Avexitide for Treatment of Post-Bariatric Hypoglycemia	Recruiting	3	75	US	Avexitide, exendin 9-39, Placebo	Amylyx Pharmaceuticals Inc.	Post Bariatric Hypoglycemia	03/26	10/26
VICTORION-1 PREVENT, NCT05739383: A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.	Active, not recruiting	3	14013	Europe, Canada, US, RoW	Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL, KJX839, Placebo in 1.5ml	Novartis Pharmaceuticals	Primary Prevention of Atherosclerotic Cardiovascular Disease	04/29	04/29
PASIPHY, NCT05928390: Pasireotide s.c. in Patients With Post-Bariatric Hypoglycaemia	Recruiting	2	72	Europe, US	Pasireotide Diaspartate, Pasireotide	RECORDATI GROUP	Post-Bariatric Hypoglycemia	04/25	04/26
NCT06240455: Phase 2 Study to Assess Efficacy & Safety of WP1302 Prevent Relapse of MMI W/draw in Subj. W/ Graves' Dz	Suspended	2	176	US	WP1302, WP1302 placebo, methimazole	Worg Biotherapeutics Inc.	Graves Disease	12/28	06/30

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Gammon, John
MUIR-3, NCT06347133: Phase 3 Study of Plozasiran in Adults With Hypertriglyceridemia	Recruiting	3	1328	Europe, Canada, US, RoW	Plozasiran Injection, ARO-APOC3, Placebo	Arrowhead Pharmaceuticals	Hypertriglyceridemia	07/26	10/26
SHASTA-3, NCT06347003: Study of Plozasiran (ARO-APOC3) in Adults With Severe Hypertriglyceridemia	Recruiting	3	405	Europe, Canada, US, RoW	Plozasiran Injection, ARO-APOC3, Placebo	Arrowhead Pharmaceuticals	Severe Hypertriglyceridemia	07/26	10/26
Watwe, Veena
MUIR-3, NCT06347133: Phase 3 Study of Plozasiran in Adults With Hypertriglyceridemia	Recruiting	3	1328	Europe, Canada, US, RoW	Plozasiran Injection, ARO-APOC3, Placebo	Arrowhead Pharmaceuticals	Hypertriglyceridemia	07/26	10/26
SHASTA-3, NCT06347003: Study of Plozasiran (ARO-APOC3) in Adults With Severe Hypertriglyceridemia	Recruiting	3	405	Europe, Canada, US, RoW	Plozasiran Injection, ARO-APOC3, Placebo	Arrowhead Pharmaceuticals	Severe Hypertriglyceridemia	07/26	10/26
LUCIDITY, NCT06747468: Avexitide for Treatment of Post-Bariatric Hypoglycemia	Recruiting	3	75	US	Avexitide, exendin 9-39, Placebo	Amylyx Pharmaceuticals Inc.	Post Bariatric Hypoglycemia	03/26	10/26
VICTORION-1 PREVENT, NCT05739383: A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.	Active, not recruiting	3	14013	Europe, Canada, US, RoW	Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL, KJX839, Placebo in 1.5ml	Novartis Pharmaceuticals	Primary Prevention of Atherosclerotic Cardiovascular Disease	04/29	04/29
PASIPHY, NCT05928390: Pasireotide s.c. in Patients With Post-Bariatric Hypoglycaemia	Recruiting	2	72	Europe, US	Pasireotide Diaspartate, Pasireotide	RECORDATI GROUP	Post-Bariatric Hypoglycemia	04/25	04/26
NCT06240455: Phase 2 Study to Assess Efficacy & Safety of WP1302 Prevent Relapse of MMI W/draw in Subj. W/ Graves' Dz	Suspended	2	176	US	WP1302, WP1302 placebo, methimazole	Worg Biotherapeutics Inc.	Graves Disease	12/28	06/30